BiotechTube
CardiaTec

CardiaTec

Cambridge, United Kingdom· Est.
cardiatec.ai
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CardiaTec is a UK-based, early-stage biotechnology company applying artificial intelligence and multiomics analysis to revolutionize cardiovascular drug discovery. Founded in 2021 as a University of Cambridge spin-out, the company is constructing a proprietary database of human cardiac tissue data (genomics, epigenomics, transcriptomics, proteomics) sourced from a network of 65 hospitals. With $6.5M in Seed funding and a world-class team, CardiaTec aims to address the significant unmet need in cardiovascular disease by using its platform to identify and validate novel therapeutic targets, moving into preclinical drug development.

Cardiovascular Disease

Technology Platform

Integrated platform combining proprietary human cardiac tissue multiomics data generation (genomics, epigenomics, transcriptomics, proteomics) from a network of 65 hospitals with advanced machine learning and multilayer computational modeling to discover novel therapeutic targets.

Opportunities

Cardiovascular disease represents a massive, underserved market with a critical need for novel therapeutic mechanisms, creating a significant opportunity for a first-mover with a disruptive platform.
The successful application of AI/multiomics in oncology provides a validated blueprint for value creation that can be replicated in cardiology.
Strategic partnerships with large pharmaceutical companies seeking to replenish their cardiovascular pipelines offer a near-term path to non-dilutive funding and validation.

Risk Factors

The core scientific risk is that the complex biology of cardiovascular disease may not yield to the multiomics/AI approach, resulting in a failure to identify viable drug targets.
The company faces significant execution risk in transitioning from a data science platform to a drug discovery and development entity, requiring different expertise and substantially more capital.
Competition from large, well-resourced pharmaceutical companies and other AI-biotechs entering the cardiovascular space is intensifying.

Competitive Landscape

CardiaTec competes with large pharma cardiovascular divisions and biotechs using traditional discovery methods. Its primary differentiator is its focused, proprietary human tissue multiomics database. It also competes with broader AI-drug discovery platforms (e.g., Recursion, Exscientia, Insilico Medicine) that may have cardiovascular programs, though few are as specialized in cardiac tissue. Its main competitive advantage is the depth and clinical relevance of its exclusive data asset.

More companies in United Kingdom →